Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain
Authors
Keywords
Asthma, Indirect Cost, Salmeterol, Asthma Control, Asthma Exacerbation
Journal
CLINICAL DRUG INVESTIGATION
Volume 36, Issue 7, Pages 567-578
Publisher
Springer Nature
Online
2016-05-03
DOI
10.1007/s40261-016-0402-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of asthma therapy: a comprehensive review
- (2015) Javier Domínguez-Ortega et al. JOURNAL OF ASTHMA
- Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective
- (2014) Alberto Nahon Levy et al. JOURNAL OF ASTHMA
- Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
- (2013) Nicola A. Hanania et al. ANNALS OF INTERNAL MEDICINE
- Does Omalizumab Make a Difference to the Real-life Treatment of Asthma Exacerbations?
- (2013) Lamiae Grimaldi-Bensouda et al. CHEST
- Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma
- (2013) Kate McKeage DRUGS
- Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
- (2013) Neil Barnes et al. JOURNAL OF ASTHMA
- Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry
- (2013) Luis Pérez de Llano et al. JOURNAL OF ASTHMA
- The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma
- (2013) G.-J. Braunstahl et al. RESPIRATORY MEDICINE
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
- (2013) Don Husereau et al. VALUE IN HEALTH
- The association between asthma control, health care costs, and quality of life in France and Spain
- (2013) Marianne Doz et al. BMC Pulmonary Medicine
- A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Omalizumab on Asthma Control in Patients with Persistent Allergic Asthma
- (2012) Jose Bardelas et al. JOURNAL OF ASTHMA
- Longitudinal Changes in Asthma Control with Omalizumab: 2-Year Interim Data from the EXCELS Study
- (2012) Mark D. Eisner et al. JOURNAL OF ASTHMA
- Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches
- (2012) María Del Carmen Vennera et al. JOURNAL OF ASTHMA
- A 36-Month Study on the Cost/Utility of Add-On Omalizumab in Persistent Difficult-to-Treat Atopic Asthma in Italy
- (2012) Roberto Walter Dal Negro et al. JOURNAL OF ASTHMA
- Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands
- (2012) Floortje van Nooten et al. JOURNAL OF MEDICAL ECONOMICS
- Omalizumab in patients with severe asthma: the XCLUSIVE study
- (2011) Christian Schumann et al. Clinical Respiratory Journal
- Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics
- (2011) Gert-Jan Braunstahl et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma
- (2010) Stephanie Korn et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Factors Associated With the Control of Severe Asthma
- (2010) Juan Luis Rodriguez Hermosa et al. JOURNAL OF ASTHMA
- Italian real-life experience of omalizumab
- (2010) M. Cazzola et al. RESPIRATORY MEDICINE
- Effects of omalizumab on markers of inflammation in patients with allergic asthma
- (2009) S. Holgate et al. ALLERGY
- The minimally important difference of the Asthma Control Test
- (2009) Michael Schatz et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany
- (2009) S. Korn et al. RESPIRATORY MEDICINE
- “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study
- (2009) G. Brusselle et al. RESPIRATORY MEDICINE
- Omalizumab
- (2008) Greg L Plosker et al. BIODRUGS
- Effectiveness of omalizumab (Xolair®) in the first patients treated in real-life practice in France
- (2007) Mathieu Molimard et al. RESPIRATORY MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More